Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Mats Jerkeman*, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H. Geisler, Kirsten Grønbæk, Arne Kolstad

*Corresponding author af dette arbejde
58 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab